Oculopharyngeal Muscular Dystrophy (OPMD) Market Outlook:
Oculopharyngeal Muscular Dystrophy (OPMD) Market size was valued at USD 5.11 billion in 2025 and is expected to reach USD 19.11 billion by 2035, registering around 14.1% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of oculopharyngeal muscular dystrophy is evaluated at USD 5.76 billion.
The market growth is on account of the rising prevalence of OPMD among the growing middle-aged population. According to MedlinePlus, muscular disease affects 1-100,000 people, especially occurring in the middle-aged population mostly after the age of 45. Affected patients can usually first experience weakness of the muscles in both eyelids that causes droopy eyelids and develop weakness in throat muscles making it hard for the patient to see or swallow.
Furthermore, other factors that are believed to fuel the growth of the market are advancements in symptomatic treatments like CP myotomy, and gastrostomy feeding tube insertion which are mostly aimed at reducing the symptoms and gaining signs for the comfort and well-being of the patients. This factor provides an additional opportunity for key players present in the market to expand their research and development activities.
